BioSpace News Archive

According to the report, the global positron emission tomography scanners market was valued at US$ 915.5 Mn in 2019 and is projected to expand at a CAGR of 3% from 2020 to 2030.

The demand within the global healthcare e-commerce market is growing on back of continuous advancements in the e-commerce industry and online sales of medication.

Acetylcholine is a major neurotransmitter of the parasympathetic nervous system. It is an ester of choline and acetic acid and functions as a transmitter of nerve impulses within the central and peripheral nervous systems.

Wearable devices and non-invasive are trending in the healthcare sector. Hence, companies are harnessing advantages of wearable devices in fetal monitoring systems.

Loss of neutrophils causes disruption of immune defense mechanisms and increases the likelihood for infections. Neutropenia is frequently associated with cancer chemotherapy and developed by majority of cancer patients during chemotherapy.

Anti-infective agents are drugs used for the purpose of killing and/or suppressing the infection causing organisms from invading the host by means of its replication or releasing variety of toxins into the host.

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering. Forte intends to use the net proceeds of the offering for working

CONMED Corporation (NYSE: CNMD) today announced financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Highlights Sales of $237.8 million increased 1.8% year over year as reported and in constant currency. Domestic revenue increased 4.7% year over year. International revenue decreased 1.7% as reported and in constant currency. Diluted net earnings per share

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2020 after the market closes on Wednesday, November 4, 2020. MacroGenics will host a conference call to discuss the financial results and recent corporate prog

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the third quarter ended September 30, 2020 will be released after the close of market on Thursday, November 12, 2020. About Histogen Inc. Histogen Inc. is a clin